Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Lenvatinib Plus TACE for Large Hepatocellular Carcinoma
NCT05171335Phase 2Completed
- Sponsor
- Houston Methodist Research Institute
- Start
- Aug 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Houston Methodist Research Institute. Primary endpoint: Percent Tumor Necrosis. Started Aug 2022; status: completed.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05171335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171335.